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Abstract
OBJECTIVE: To observe the effect of compound
Zhebei granules (CZBG) with chemotherapy in the
treatment of refractory acute leukemia.
METHODS: In this multicenter, double-blind, place-
bo-controlled clinical trial, we used a central (on-
line) randomization system to assign 235 patients
to two treatment groups. A total of 118 patients re-
ceived chemotherapy combined with CZBG (4 g,
twice daily) and 117 patients received chemothera-
py plus placebo. The clinical efficacy was evaluated
at the end of one chemotherapeutic cycle.
RESULTS: In the full analysis set, in which deaths
due to disease progression were regarded as ineffi-
cacy, the rates of complete remission (CR) and par-
tial remission (CR + PR) were 32.35% and 50.00% ,
respectively, for the chemotherapy combined with
CZBG group, and 23.08% and 35.58%, respectively,
for the chemotherapy plus placebo group. There
was a statistically significant difference between
the two groups according to a χ2 test (P < 0.05). In
the per protocol analysis set (PPS), the CR (33.67%),
CR+PR (52.04%) response rates for the chemothera-
py plus CZBG group were significantly different
from the response rates of the control group (CR:
24.24% and CR+PR: 37.37%), respectively (P < 0.05).
CONCLUSION: CZBG plus chemotherapy can im-
prove the clinical remission rate of refractory acute
leukemia after one just one therapeutic cycle.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Acute leukemia (AL) is a hematologic malignancy that
is a serious hazard to health. Currently, chemotherapy
remains the most important therapeutic option for AL,
but 30% of patients do not respond to treatment. In
addition, 40%-60% of patients become unresponsive
to treatment after relapse, and are subsequently reas-
sessed as having refractory acute leukemia (RAL). RAL
has short overall survival and is a challenge in the treat-
ment of AL.1-2 As such, developing new methods to im-
prove the chemotherapy remission rate of RAL remains
of the upmost importance.
Traditional Chinese Medicine has been used for thou-
sands of years to treat or prevent diseases, including
cancer. In recent years, it has been shown that some
herbal products display anticancer properties.3 Com-
pound Zhebei granules (CZBG) are an herbal medi-
cine prepared from three herbs: Zhebeimu (Bulbus Frit-
illariae Thunbergii), Fangji (Radix Stephaniae Tetran-
drae), and Chuanxiong (Rhizoma Chuanxiong). Previ-
ously, using in vivo and in vitro models we have shown
that multidrug resistance (MDR) of leukemic cells can
be reversed. The mechanism of action of CZBG is
through induction of apoptosis and the inhibition of
resistance-associated enzymes and drug resistance-asso-
ciated membrane protein expression.4-10
In this study, we designed a randomized, multicenter,
double-blind, placebo-controlled clinical trial under
good clinical practice guidelines to study the effect of
CZBG plus chemotherapy on the remission rate of pa-
tients with RAL.
MATERIALS ANDMETHODS
Patients
The study participants were inpatients between May
2007 and December 2009 at Dongzhimen Hospital,
which is affiliated with the Beijing University of Chi-
nese Medicine, the Xiyuan Hospital, which is affiliated
with the China Academy of Chinese Medical Sciences,
the First Affiliated Hospital of Tianjin University of
Traditional Chinese Medicine, the Langfang Chinese
Medicine Hospital which is affiliated with Hebei Medi-
cal University, the First Affiliated Hospital of Guang-
zhou University of Chinese Medicine, the Chinese
Medicine Hospital of Zhejiang Province, and the First
Affiliated Hospital of the Heilongjiang University of
Chinese Medicine. The trial was approved by the eth-
ics committee of all the aforementioned hospitals, and
informed consent was obtained from all patients
(WHOICT-ChiCTR registration number: ChiC-
TR-CTR-00000410). A flowchart of the clinical trial
is included at appendix 1.
Diagnostic criteria
The AL diagnostic criteria were based on the 1987 Na-
tional Hematology Conference of Chinese Medical As-
sociation.11 These criteria include: (a) Acute onset, fe-
ver, anemia, progressive bleeding, which is accompa-
nied by tenderness of the sternum, swollen lymph
nodes, hepatomegaly or splenomegaly. (b) A dramatic
decrease in hemoglobin and platelet levels with leuke-
mia cells in the peripheral blood which account for
more than 30% of complete blood cells. (c) Extremely
active bone marrow proliferation most of which were
leukemia cells, blasts took at least 30% of bone mar-
row, and reduced levels of red blood cells and mega-
karyocytes. (d) The classification of leukemia was deter-
mined according to cell morphology, cytochemical
staining, and immunological tests (subtype classifica-
tion relied on "Diagnosis and standardization of re-
sponse criteria for blood disease" edited by Zhang Zhi-
nan11). The three subtypes of acute lymphoblastic leu-
kemia (ALL) included: L1, L2, and L3, while the seven
subtypes of acute myelocytic leukemia (AML) were:
M0, M1, M2, M4, M5, M6, and M7. The RAL diag-
nostic criteria was based on the draft diagnostic criteria
of the RAL proposal of the Second National Refractory
Leukemia Workshop, held in October 1999 (the Fu-
zhou meeting).12 These criteria included: (a) Failure of
the patient to obtain complete remission (CR) after
two cycles of standard induction chemotherapy; (b)
the patient relapsed during consolidation therapy after
achieving CR during induction therapy; (c) their dis-
ease transformed from blast crisis of chronic myeloge-
nous leukemia or from myelodysplastic syndrome; (d)
the patient was diagnosed with heterozygous (hybrid)
leukemia or leukemia with no less than two kinds of
abnormal antigen expression that failed to obtain CR
after one cycle of standard chemotherapy; or (e) their
peripheral white blood cell count was > 100.0 × 109/L.
Inclusion criteria
To be eligible for the trial the patients were required to
meet three inclusion criteria: (a) the patients met the
diagnostic criteria of AL and any one condition of
RAL; (b) the patients signed the informed consent
form; and (c) the patients had not been treated within
the previous month before the trial began with any oth-
er traditional Chinese or modern medicine.
Ineligibility criteria
Patients were excluded from the trial if they presented
with any one of the following: (a) any coexisting medi-
cal condition including severe heart, brain, liver, or kid-
ney disease; (b) mental illness; (c) glaucoma; (d) for fe-
male patients, pregnancy or currently lactating; (e) an
allergy to any herbs within the CZBG formula; and (f )
under 10 years of age or older than 80.
Exclusion criteria
Further exclusion criteria included: (a) the patient was
unable to meet the inclusion criteria during any stage
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of the trial; (b) they were unable to complete one cycle
of chemotherapy; (c) the patient required a change in
their treatment plan because of serious adverse events,
severe complications, or disease progression.
Response criteria
After one cycle of treatment, clinical efficacy and safety
evaluation data were collected. The response criteria
were based, with modifications, on the Standard of Na-
tional Leukemia Chemotherapy Symposium held by
the Professional Committee of the Chinese Medical As-
sociation of Hematology in Suzhou, Jiangsu Province,
in November 1987.13
Complete Remission (CR): (a) Bone marrow: myelo-
blast cell typeⅠ +Ⅱ (or monoblast or lymphoblast) ≤
5% , with normal red blood cell and megakaryocyte
counts. For M2b, myeloblastⅠ +Ⅱ ≤ 5% of the neu-
trophil proportion in the normal range. For M4, my-
eloblast Ⅰ + Ⅱ monoblast ≤ 5%; for M6, myeloblastⅠ +Ⅱ ≤ 5% with a generally normal ratio of erythro-
blasts and erythrocytes; and for M7, a normal ratio of
red cells and granulocytes with an absence of meg-
karyoblasts. (b) Blood count: hemoglobin (HGB) ≥
100 g/L (male) or 90 g/L (female), absolute neutro-
phils count ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, and
no leukemic cells in the peripheral blood. (c) Clinical
manifestations: no signs and symptoms of tissue infil-
tration, and the patient could lead a normal, or near
normal, life.
Morphological complete remission with abnormal
blood count (CRi): Morphology of their bone marrow
met the CR criteria, but with persistent neutropenia (<
1.0 × 109/L) or thrombocytopenia (< 100 × 109/L).
Partial Remission (PR): Myeloblast cell type Ⅰ + Ⅱ
(or monoblast or lymphoblast) > 5% and ≤ 20%, clini-
cal manifestations, or blood count that did not reach
the CR standards.
No Remission (NR): Bone marrow morphology, blood
count and clinical manifestations all failed to meet the
criteria noted above.
Randomization and blinding
The randomization process was undertaken using the
Central Randomization System of the Clinical Evalua-
tion Center of the China Academy of Chinese Medical
Sciences. Randomized numbers were accessed via tele-
phone or internet before each clinical trial center re-
cruited their eligible patients. Patients were then as-
signed to either the CZBG plus chemotherapy group
or the chemotherapy plus placebo group according to
the randomized number of their drugs. All the partici-
pants, care providers, and outcome assessors were blind-
ed throughout the trial.
Treatment
The chemotherapy regimens were determined based on
results from previous clinical trials and the consensus
of principal investigators from all clinical trial centers.
One cycle of vincristine, daunorubicin, cyclophospha-
mide (VDC)/L-asparaginase, dexamethasone (LD),
methotrexate, oncovin, L-asparaginase, dexamethasone
(MOAD) or mesna, ifosfamide, novantrone, etoposide
(MINE) was administrated to the ALL patients, while
homoharringtonine, Ara-C, etoposide (HAE), mesna,
Ara-C, etoposide (MAE) or cytarabine, aclarubicin,
granulocyte colony-stimulating factor (CAG) was ad-
ministered to the AML patients.
Patients were given CZBG (1 × 4 g bag, twice daily) or
a placebo, which was started three days before chemo-
therapy was commenced, then given for 14 consecutive
days. The placebo was designed to be exactly the same
as CZBG with regards to its packaging, size, appear-
ance, color, taste, smell, and dosage form.
Configuration method of CZBG: the daily dosage of
each herb was: Zhebeimu (Bulbus Fritillariae Thunber-
gii) 12 g, Fangji (Radix Stephaniae Tetrandrae) 12 g, Ch-
uanxiong (Rhizoma Chuanxiong), 6 g (all referring to
the weight of original herbal pieces prepared for mak-
ing the decoction). The herbal medicine ratios used for
the preparation of the granules were: Zhebeimu (Bul-
bus Fritillariae Thunbergii) 5∶1, Fangji (Radix Stephani-
ae Tetrandrae) 3.3∶1, and Chuanxiong (Rhizoma Ch-
uanxiong) 2.9∶1.
The granules were prepared using the following meth-
od. The herbs were boiled in water for 2 h: 5 kg of Zhe-
beimu pieces (Fritillaria thunbergii Miq) in 40 L of wa-
ter, 3.3 kg of Fangji pieces (Radix Stephaniae Tetran-
drae) in 26.4 L of water, and 2.9 kg of Chuanxiong
(Rhizoma Chuanxiong) in 19.8 L of water. The solu-
tions were then filtered to collect the solid residues be-
fore more water was added (40 L, 26.4 L, and 19.8L
water, respectively), the solutions boiled again for 1.5 h,
before the solutions were filtered a second time. The fil-
trates from the two processes were mixed together and
concentrated to produce granules. The relative daily
amounts of each granule type were then weighed and
mixed according to the prescribed dosage: Zhebeimu
(Bulbus Fritillariae Thunbergii) 2.4 g, Fangji (Radix
Stephaniae Tetrandrae) 3.6 g and Chuanxiong (Rhizoma
Chuanxiong) 2.0 g. This daily dose was packed into
two bags, 4 g each, ready for serving. The CBZG was
provided by Beijing Tcmages Pharmaceutical Co., Ltd.,
Supportive measures
The supportive measures for the patients included: us-
ing antibiotics from the same category and the same
generation for infection or fever; red blood cell transfu-
sion for patients with hemoglobin levels < 60 g/L or
platelet levels < 30 × 109 g/L; and G-CSF for patients
with a white blood cell count < 2.0 × 109 g/L. No oth-
er herbal decoction or Chinese medicine was given dur-
ing the trial, nor was any other medication with a de-
monstrable reversal effect on multidrug resistance al-
lowed during the study.
Statistical analysis
The trial data were processed using SAS (version 9.1.3,
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SAS Institute, Beijing, China). Rank sum tests were
used to compare the response rates between the two
groups, while χ2 tests were used to control the multi-
center effect when determining the chemotherapy effi-
cacy. All statistical analyses were two-sided tests. A P
value ≤ 0.05 was considered statistically significant.
RESULTS
Clinical data
Patient Characteristics: between May 2007 and Decem-
ber 2009, 269 patients were diagnosed with RAL after
screening from seven first-level, first-grade Chinese hos-
pitals; a total of 238 patients were enrolled in our
study. Three patients were excluded before the trial:
one patient did not meet the age criteria (82 years old),
one was missing baseline data, and another withdrew
their consent. In total, 21 patients were excluded after
the trial began due to: loss during follow up, leaving
the clinical trial, seriously lacking baseline data, and re-
fusing to provide clinical evidence for efficacy evalua-
tion. During the trial there were 20 deaths, eight of
which had clinical evidence of disease progression (ele-
vated leukemia cells in peripheral blood count), while
the other 12 died of complications during treatment.
In accordance with the statistical analysis plan, 235 pa-
tients entered the full analysis set (FAS) with 118 in
the chemotherapy with CZBG group (treatment
group) and 117 in chemotherapy plus placebo group
(control group). There were 197 patients entered in
the per protocol analysis set (PPS) with 98 patients in
the treatment group and 99 in the control group (Fig-
ure 1). There were nine deaths in the treatment group,
and 11 in the control group. None of the deaths were
related to treatment with CZBG, and there was no sig-
nificant difference of in the number of deaths between
the two groups. The relative information for the pa-
tients is given in Table 1. A comparison of two groups'
baseline information showed that there was no statisti-
cal significance with regard to sex (P = 0.6511), age
(P = 0.57), type of AL (P = 0.784), etiological classifi-
cation of RAL (P = 0.743) or chemotherapy regimen
(P > 0.05) (Table 2).
Clinical efficacy
As was shown in Tables 3 and 4, the FAS and PPS CR
rates of the treatment (32.35% , n = 33 for FAS;
Analysed (n = 117)
Excluded from analysis (one withdrew the con-
sent; one without complete baseline information)
(n = 2)
Assessed for eligibility (n = 269)
Excluded (n = 31)
Not meeting inclusion criteria (n = 31)
Randomized (n = 238)
Allocated to chemotherapy plus compound zhebei
granules (n = 119)
Received allocated intervention (n = 118)
Did not receive allocated intervention (exceed the
age limit) (n = 1)
Allocated to chemotherapy plus placebo (n = 119)
Received allocated intervention (n = 117)
Did not receive allocated intervention (one with-
drew the consent; one without complete baseline
information) (n = 2)
Lost to follow-up (incomplete information) (n = 4)
Discontinued intervention (4 disease progressed; 4
autonomously discharged; 3 stopped the treat-
ment; 3 had cerebral haemorrhage; 1 had septice-
mia; 1 had acute necrotizing pancreatitis) (n = 16)
Lost to follow-up (incomplete information) (n = 2)
Discontinued intervention (5 disease progressed; 5
autonomously discharged; 1 denied chemotherapy;
1 stopped the treatment; 2 had cerebral haemor-
rhage; 1 had cerebral infection; 1 had acute respira-
tory distress syndrome) (n = 16)
Analysed (n = 118)
Excluded from analysis (Exceed the age limit)
(n = 1)
Figure 1 Flow chart of the study
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33.67%, n = 33 for PPS) were both higher than those
in the control groups (23.07% , n = 24 for FAS;
24.24%, n = 24 for PPS). The difference between the
two groups was both statistically significant (P =
0.0444, Z = －2.01 for FAS and P = 0.0476, Z = －
1.9795 for PPS). Moreover, both the FAS and PPS CR
+ PR rates were significantly higher (P = 0.0328 for
FAS and P = 0.038 for PPS) in the treatment group
(50.00%, n = 51 for FAS; 52.04%, n = 51) than those
in the control group (35.58% , n = 37 for FAS;
37.37%, n = 37 for PPS). The above results indicated
that the treatment group had higher chemotherapy-re-
lated remission rates compared with the control group
after just one cycle of treatment.
DISCUSSION
The main active ingredients of CZBG are peimine, tet-
randrine, and tetramethylpyrazine. Our previous re-
search showed that CZBG-containing serum can inhib-
it the proliferation of L1210/CDDP cells, inhibit the
efflux of anticancer drugs from K562/A02 cells, and in-
duce apoptosis of K562/A02 cells.4,5 We have also
shown that high and medium doses of CZBG can en-
hance the inhibitory effect of doxorubicin on K562/
A02 tumor xenografts, and reduce the expression of
MDR1 genes in transplanted tumor tissue.6,7 CZBG
can also increase the apoptosis-inducing effect of doxo-
rubicin on K562/A02 xenograft tumors, reduce the
high expression of BCL-2 proteins, and up-regulate
BAX protein expression.8 Finally, it has been shown
that CZBG works synergistically with doxorubicin to
inhibit the expression of resistance-associated enzymes
(e.g. GSH, TopoII) and membrane proteins (e.g. P-gp,
MRP) of K562/A02 xenograft tumor tissue.9,10 To dem-
onstrate the clinical efficacy of CZBG, we designed
this randomized, multi-center, double-blind, place-
bo-controlled clinical trial and chose chemotherapy re-
mission rates, which is the internationally recognized
Table 1 Number of patients for all trial centers
Name of Site
Dongzhimen Hospital Affiliated to Beijing University of
Chinese Medicine
Xiyuan Hospital Affiliated to China Academy of Chinese
Medical Sciences
First Affiliated Hospital of Tianjin University of Traditional
Chinese Medicine
Langfang Chinese Medicine Hospital Affiliated to Hebei
Medical University
First Affiliated Hospital of Guangzhou University of Chinese
Medicine
Chinese Medicine Hospital of Zhejiang Province
First Affiliated Hospital of Heilongjiang University of Chinese
Medicine
Total
Patients
screened
46
40
41
42
62
20
18
269
Patients
enrolled
40
40
40
40
40
20
18
238
Patients
excluded
2
0
0
0
0
0
1
3
Patients
lost
1
7
4
3
3
0
3
21
Number
of deaths
2
2
5
5
0
1
2
17
Complete
patients
35
31
31
32
37
19
12
197
Characteristic
Age (years)
Male [n (%)]
Acute leukemia types [n (%)]
Sub-types of RAL [n (%)]
AML
ALL
NR2
Relapse
Blast crisis of CML
MDS transformation
Heterozygous leukemia
WBC > 100 × 109/L
Control group
(n = 117)
43.22 ± 18.59
67 (57.26)
91 (77.78)
26 (22.22)
28 (23.93)
50 (42.74)
5 (4.27)
20 (17.09)
5 (4.27)
9 (7.69)
Treatment group
(n = 118)
44.57 ± 17.41
71 (60.70)
90 (76.27)
28 (23.73)
36 (30.51)
42 (35.59)
7 (5.93)
22 (18.64)
5 (4.24)
6 (5.08)
Notes: compound Zhebei granules (treatment group) or placebo (control group) was given for 14 consecutive days, starting three days be-
fore chemotherapy, with patients taking one bag (4 g) twice a day. The placebo was designed to be exactly the same as CZBG with regard
to packaging, size, appearance, color, taste, smell, and dosage form. AML: acute myelocytic leukemia; ALL: acute lymphoblastic leukemia;
RAL: refractory acute leukemia; NR2: no remission 2, refers to no remission after two cycles of standard chemotherapy; CML: chronic my-
elocytic leukemia; MDS: myelodysplastic syndrome. Chemotherapy regimens were determined based on consensus of principal investiga-
tors from all clinical trial centers. There were no significant differences in the age (P = 0.57), sex (P = 0.6511), and of type of AL (P =
0.784) between the treatment and control groups.
Table 2 Baseline characteristics of treatment group and control group ( xˉ ± s)
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golden standard for AL clinical efficacy evaluation, as
our primary indicator. From our results, we have
shown that when CZBG is combined with chemother-
apy, it can improve the remission rate of RAL after just
one chemotherapeutic cycle. From the FAS analysis,
the CR + PR rates of the treatment and control groups
were 48.11% and 34.26% respectively. The difference
between the two groups was statistically significant
(P = 0.02). From the PPS analysis, the CR+PR rates of
the treatment and control groups were 52.04% and
37.37% respectively. There was a significant difference
between two groups (P = 0.038). Compared with the
control group, the CR (CRi) and CR+PR rates of the
treatment group increased by 9.22% and 14.42% for
FAS, and 9.43% and 14.67% for PPS, respectively.
The above results show that CZBG in combination
with chemotherapy can significantly improve the remis-
sion rate after just one treatment cycle and shows good
prospects for clinical application. There are however
problems that may compromise the results. First, the
course of therapy in our treatment period was 14 days,
which is a relatively short period, so it may affect our
findings regarding the treatment efficacy. Second, an
ideal chemotherapy remission rate for the initial treat-
ment of AL cannot always be achieved by one cycle of
chemotherapy; multiple cycles of chemotherapy are
usually required. For RAL, additional cycles of chemo-
therapy are needed because RAL is generally non-re-
sponsive to chemotherapy.14 Although this clinical trial
shows a relatively high rate of remission, there is still a
lower CR rate compared with some other targeted
agents15-16 with a CR rate of 42%-50% . To address
these limitations, we recommend further trials that in-
clude more than one cycle of chemotherapy, and that
the observation period be extended.
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